NASDAQ · SMMT
Summit Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SMMT: Nov 2, 2026
Summit Therapeutics Inc. Common Stock is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.28. The reported EPS for the same quarter last year was $-0.31.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.28 | $-0.27 | $-0.29 | 3 |
| Dec 2026 | $-0.40 | $-0.27 | $-0.65 | 3 |
| Mar 2027 | $-0.28 | $-0.26 | $-0.29 | 2 |
| Jun 2027 | $-0.28 | $-0.26 | $-0.30 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Barchart- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- RTTNews · Oct 26, 5:55 AM EDTLunit And Summit Collaborate On AI-Powered Biomarker Discovery For Ivonescimab(RTTNews) – Lunit Inc. (328130.KQ) and Summit Therapeutics Inc. (SMMT) announced a research agreement to evaluate Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumour microenvironment analysis to support Summit's immuno-oncology development programs for ivonescimab.
- Zacks · Oct 22, 9:49 AM EDTSummit Expands Ivonescimab Development Into Biliary Tract CancerSMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.
- RTTNews · Oct 21, 10:19 AM EDTAkeso's Ivonescimab To Be Evaluated In Global Phase II/III Biliary Tract Cancer Trial(RTTNews) – Akeso, Inc. (9926.HK) announced that its partner Summit Therapeutics (SMMT) has entered into a clinical trial collaboration with ECOG-ACRIN Cancer Research Group to evaluate Ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer.
- Zacks · Oct 21, 10:00 AM EDTCan Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
- Zacks · Oct 5, 9:37 AM EDTSMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
- RTTNews · Oct 5, 7:29 AM EDTSummit Therapeutics Secures $2B Strategic Investment From AstraZeneca(RTTNews) – Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab, an investigational PD-1/VEGF bispecific antibody.
- RTTNews · Oct 2, 12:13 PM EDTWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) – The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov
- RTTNews · Oct 2, 3:40 AM EDTDaiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies(RTTNews) – Daiichi Sankyo (4568.TS) and AstraZeneca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumor types, expanding efforts
- RTTNews · Oct 2, 2:59 AM EDTDaiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab(RTTNews) – Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumors, including lung and brea
- Barchart · Sep 30, 1:34 PM EDTStocks Settle Mixed as Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.17% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.21%. December E-mini S&P futures (ESZ26 ) fell -0.15%, and December E-mini…
- Barchart · Sep 29, 7:19 PM EDTStocks Turn Mixed as Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) is down by -0.11% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.24%. December E-mini S&P futures (ESZ26 ) are down -0.18%, and December E-mini…
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Summit Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.